Announcement for completion of the capital
reduction as a result of the cancellation of treasury
stocks.
Date of events
2022/01/24
To which item it meets
paragraph 36
Statement
1.Date of the competent authority��s approval of capital
reduction:2022/01/20
2.Date of completion of capitalization change registration:2022/01/20
3.Effect on the financial statements (including any
discrepancy between the amount of paid-in capital and
the no.of shares outstanding, and the effect on net
worth per share):
(1)The paid in capital before the retirement of treasury shares was
NT$472,460,760. The paid in capital after the retirement of treasury
shares is NT$459,580,760.
(2)The number of shares outstanding before the retirement of treasury
shares was 47,246,076 shares. The number of shares outstanding
after the retirement of treasury shares is 45,958,076 shares.
The difference is 1,288,000 shares.
(3)The net asset value per share was NT$18.09 before
retirement. It is NT$18.59 after retirement.
(based on 2021Q3 financial report)
4.Plan for expected exchange of shares:NA
5.Estimated no.of listed common shares after capital
reduction and new issue:NA
6.Estimated no.of listed
common shares as a percentage
of issued common shares after capital reduction and
new issue (No.of common
shares after capital reduction/No.of issued
common shares):NA
7.Countermeasures for poor circulation of equity if the
aforesaid estimated no.of
listed common shares does
not reach 5 million shares
and the percentage does not
reach 25% after capital
reduction:NA
8.Any other matters that need
to be specified:
The Company received the letter of approval on 2022/01/24.
Attachments
Original Link
Original Document
Permalink
Disclaimer
CVC Technologies Inc. published this content on 24 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 January 2022 07:23:07 UTC.
CVC Technologies Inc. is principally engaged in the manufacture and sales of pharmaceutical packaging equipment. The Company's products include tablet and capsule counting production lines, liquid filling lines, powder production lines and optical detectors. Its tablet and capsule counting production lines are mainly applied to the bottled packaging production of tablets and capsules. Its liquid filling lines are mainly applied to the bottled packaging production of oral solutions. Its powder production lines are mainly applied to the bottled packaging production of drug powder. Its optical detectors are mainly applied to the inspection of various packaged bottled pharmaceutical agents for injection applications. The Company mainly distributes its products in America, India and Mainland China.